[The use of ixel in the treatment of depression in patients with chronic schizophrenia].
An open non-controlled 12-week study of 30 patients with chronic schizophrenia with mild and moderate depression has been carried out. Ixel was administered in dosage 100-200 mg daily along with the basic antipsychotic therapy (haloperidol, olanzapine, quetiapine, risperidone, paliperidone). Patient's state was assessed with the Clinical Global impression scale (CGI), the Hamilton depression scale (HAM-D-21) and the Positive and Negative Syndromes scale (PANSS). Percentage of responders on CGI was 73.3%. A significant (p<or=0.01) reduction (by 88% from baseline) of mean HAM-D scores was observed. Along with thymoanaleptic effect, ixel exerted an effect on depressive symptoms that were comorbid to negative disorders and resistant to standard antidepressive therapy. Ixel was well tolerated and did not cause sedation and behavioral toxicity and was compatible to both traditional and modern atypical antipsychotics.
I Iu
IIu
Dorozhenok
M A
MA
Terent'eva
E I
EI
Voronova
D000328:Adult; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D003521:Cyclopropanes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000078764:Milnacipran; D012559:Schizophrenia / Q000150:complications*
D000928:Antidepressive Agents; D003521:Cyclopropanes; D000078764:Milnacipran